Publications 1. 2. Burzykowski T., Buyse M., Yothers G., Sakamoto J., Sargent D.: Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Date Anal. 14(1):54-64,2008 Cho H., Tsuburaya A., Sakamoto J., Morita S., Oba K., Yoshikawa T., Miyajima N.: A Randomized Phase II Trial of Preoperative Exercise to Reduce Operative Risk in Gastric Cancer Patients with Metabolic Syndrome: Adjuvant Exercise for General Elective Surgery (AEGES) Study Group. Jpn J Clin Oncol 38(1):71-73,2008 3. Saji S., Toi M., Morita S., Iwata H., Ito Y., Ohno S., Kobayashi T., Hozumi Y., Sakamoto J.: Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine(Xeloda)in Combination with Epirubicin and Cyclophoshamide(CEX)in Patients with lnoperable or Metastatic Breast Cancer. Oncology 72(5-6) 330-337,2007 4. Enkhbold S., Tugsdelger S., Morita S., Sakamoto J., Hamajima N.: HIV/AIDS RELATED KNOWLEDGE AND RISK BEHAVIORS AMONG FEMAIL SEX WORKERS IN TWO MAJOR CITIES OF MONGOLIA. Nagoya J. Med. Sci 69(3,4).157-165,2007 5. Kobayashi M., Sakamoto J., Namikawa T., Okamoto K., Kitagawa H., Hokimoto N., Okabayashi T., Hanazaki K.: Modified Funada’s Gastropexy Needle for Mesh Fixation in the Subcutaneous Layer Using Thread During Laparoscopic Incisional Hernia Repair. Surg Laparosc Endosc Percutan Tech 17(4):296-299,2007 6. Kodera Y., Ito S., Mochizuki Y., Fujitake S., Koshikawa K., Kanyama Y., Matsui T., Kojima H., Takase T., Ohashi N., Fujiwara M., Sakamoto J., Nakao A., Chubu Clinical Cancer Group. : A Phase II Study of Weekly Paclitaxel as Second-line Chemotherapy for Advanced Gastric Cancer(CCOG0302 Study) ANTICANCER RESEARCH 27:2667-2672,2007 7. 8. Morita S., Kaptein A A., Oba K., Sakamoto J. : The domain structure of the EORTC QLQ-STO22 supported by Japanese validation data. Psycho-Oncology ,2007 (online) Kim Y H., Yamaguchi K., Bang Y., Takiuchi H., Kag W K., Sato A., Kang Y., Sakamoto J., Abe C., Sakata Y.: Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea-Japan Collaborative Study Group Trial. Jpn J Clin Oncol 37(7):501-508,2007 9. Kato T., Mishima H., Ikenaga M., Murata K., Ishida H., Fukunaga M., Ota H., Tominaga S., Ohnishi T., Amano M., Ikeda K., Ikeda M., Sekimoto M., Sakamoto J., Monden M.: A Phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol ,61:275-81,2008 10. Masuda N., Taguchi T., Nakayama T., Shiba E., Watatani M., Kurebayashi J., Takatsuka Y., Sakamoto J., Noguchi S., Kinki Breast Cancer Study Group (KBCSG).: Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent
breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group. Cancer Chemother Pharmacol ,2007 (online) 11. Kawakami M., Oka Y., Tsuboi A., Harada Y., Elisseeva O A., Furukawa Y., Tsukaguchi M., Shirakata T., Nishida S., Nakajima H., Morita S., Sakamoto J., Kawase I., Oji Y., Sugiyama H.: Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5µg/Body) in a Patient with Chronic Myelomonocytic Leukemia. International Journal of Hematology 85:426-429,2007 12. Morita S., Baba H., Tsuburaya A., Takiuchi H., Matsui T., Maehara Y., Sakamoto J.: A Randomized Phase II Selection Trial in Patients with Advanced//Recurrent Gastric Cancer : Trial for Advanced Stomach Cancer (TASC). Jpn J Clin Oncol 37(6):469-472,2007 13. Sakamoto J., Hamada C., Yoshida S., Kodaira S., Yasutomi M., Kato T., Oba K., Nakazato H., Saji S., Ohashi Y. : An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected cancer. British Journal of Cancer 96(8):1170-1177,2007 14. Kobayashi M., Oba K., Sakamoto J., Kondo K., Nagata N., Okabayashi T., Namikawa T., Hanazaki K.: Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Gastric Cancer 10(1):52-57,2007 15. Sakamoto J., Morita S.: From translational research to a lage randomizerd clinical trial: A long and streanuous way form bench to bedside. Nagoya J Med Sci 69(1,2):9-16,2007 16. Hara T., Omura K., Hirano M., Asada Y., Munemoto Y., Sakamoto J.: A phase I study of paclitaxel, cisplatin, and fluorouracil(TCF) for advanced gastric cancer. Cancer Chemother Pharmacol 59:631-636,2007 17. Rahman M., Awal A N., Fukui T., Sakamoto J.: Prevalence of cigarette and bidi smoking among rickshaw pullers in Dhaka city. Preventive Medicine 44:218-222,2007 18. Oba K., Teramukai S., Kobayashi M., Matsui T., Kodera Y., Sakamoto J.: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56:905-911,2007 19. Morita S., Kaptein A A., Tsuburaya A., Kodera Y., Matsui T., Sakamoto J. : Assessment and data analysis of health-related quality of life in clinical trials for gastric cancer treatments. Gastric Cancer 9(4):254-261,2006 20. Sakamoto J., Oba K., Matsui T., Kobayashi M.: Efficacy of Oral Anticancer Agents for Colorectal Cancer. Dis Colon Rectum 49(10)S82-S91,2006 21. Sakamoto J., Oriuchi N., Mochiki E., Asao T., Scott A M., Hoffman E W., Jungbluth A A., Matsui T., Lee F T.: A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. Cancer Sci 97(11)1248-1254,2006 22. Matsui T., Omura K., Kawakami K., Morita S., Sakamoto J.: Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer.
Oncology Reports 16:1111-1115,2006 23. Kinouchi T., Sakamoto J., Tsukamoto T., Akaza H., Kubota Y., Ozono S., Kanetake H., Taguchi T., Kotake., Immunotherapy Oncology Group for Renal Cell Carcinoma.: Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol 132:499-504,2006 24. Morita S., Kobayashi M., Oba K., Ichihara T., Nakao A., Sakamoto J.: Truth-telling to Patients with Advaced Canser: A Comparison between Cancer center, University Hospitals, General City Hospitals, and Private General Pracitioners in Japan. Ann. Cancer Res. Therap. 14(1)1-11,2006 25. Fukui T., Rahman M., Shimbo T., Morita S., Sakamoto J.: Recruitment of Patients for a Clinical Trial: Factors on the Physician Side and Reasons on the Patient Side. Reprinted from Internal Medicine 45:511-514,2006 26. Fukui T., Rahman M., Morita., Sakamoto J.: Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan(CASE-J)Trial: A Survey of Collaborating Physicians. Hypertens Res 29(7)471-474,2006 27. Oba K., Morirta S., Tsuburaya A., Kodera Y., Kobayashi M., Sakamoto J.: Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan. Journal of Chemotherapy 18(3)311-318,2006 28. Yoshida K., Ninomiya M., Takakura N., Hirabayashi N., Takiyama W., Sato Y., Todo S., Terashima M., Gotoh M., Sakamoto J., Nishiyama M.: Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. Clin Cancer Res 12(11),2006 29. Sakamoto J., Oba K., Matsui T., Kobayashi M.: Evidence Based Medicine in Biotherapy for Malignant Tumor. Biotherapy 20(4):363-373,2006 30. Morita S., Kaptein A A., Tsuburaya A., Kodera Y., Matsui T., Sakamoto J.: Assessment and Data Analysis of Health-Related Quality of Life in Clinical Trials for Gastric Cancer treatments. Gastric Cancer 9:254-261,2006 31. Morita S., Sakamoto J.: Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design. Pharmaceut. Statist. 5:109-118,2006 32. Kobayashi M., Tsuburaya A., Nagata N., Miyashita Y., Oba K., Sakamoto J.: feasibility study of sequential paclitaxel and S-1(PTX/S-1)chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer 9:114-119,2006 33. Kobayashi M., Sakamoto J., Namikawa T., Okamoto K., Okabayashi T., Ichikawa K., Araki K.: Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 12(9):1412-1415,2006 A
34. Morita S., Oka Y., Tsuboi A., Kawakami M., Maruno M., Izumoto S., Osaki T., Taguchi T., Ueda T., Myoui A., Nishida S., Shirakata T., Ohno S., Oji Y., Aozasa K., Hatazawa J., Udaka K., Yoshikawa H., Yoshimine T., Noguchi S., Kawase I., Nakatsuka S., Sugiyama H., Sakamoto J.: A Phase I/II Trial of a WT1(Wilm’s Tumor Gene)Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Date. Jpn J Clin Oncol 36(4)231-236,2006 35. Sakamoto J., Morita S., Oba K., Matsui T., Kobayashi M., Nakazato H., Ohashi Y.: Efficacy of adjuvant Immunchemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother55:404-411,2006 36. Sakamoto J., Hamada C., Rahman M., Kodaira S., Ito K., Nakazato H., Ohashi Y., Yasutomi M.,: An individual patients data Meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer. Jnp J Oncol35(9)356-544, 2005 37. Ueda U., Yamagishi H., Ichikawa D., Morii J., Koizumi K., Kakihara N., Shimotsuma M, Takenaka A., Yamashita T., Kurioka H., Nishiyama M., Morita S., Nakamura K., Sakamoto J.: Phase Study of a combination of S-1 and weekly Paclitaxel in patients with advanced or recurrent gastric cancer. Oncology69:261-268,2005 38. Oriuchi N., Nakajima T., Mochiki E., Takeyoshi I., Kanuma T., Endo K., Sakamoto J.:A new, accurate and conventional five-point method foe quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol35(7)386-390 ,2005 39. Kondo K., Kobayashi M., Kojima H., Hirabayashi N., Kataoka M., Araki K.,Matsui T.,Takiyama w., Miyashita Y., Nakazato H., Nakao A., Sakamoto J.: Phase evaluation of continuous 5-flourouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. Jpn J Clin Oncol 35(6):332-37,2005 40. Kaptein A., Morita S., 41. Rahman M., Sakamoto J., Sakamoto J.: Quality of life in gastric cancer. World J Fukui T.: Calculation of population attributable risk for bidi Sakamoto J.: Physicians’ attitudes towards and Gastroenterol 11(21):3189-3196,2005 smoking and oral cancer in south Asia. Preventive Medicine 10:510-514,2005 42. Rahman M., Morita S., Fukui T., reasons for participation in the candesartan antihypertensive survival evaluation in Japan(CASE-J) trial. Journal of Epidemiology 15(2):38-40,2005 43. Hagino A., Hamada C., Yoshimura I., Ohashi Y., Sakamoto J., Nakazato H.: Statistical comparison of random allocation methods in cancer clinical trials. Controlled Clinical Trials 25:572-584,2004 44. Teramukai S., Matsuyama Y., Mizuno S., Sakamoto J.: Individual patient-level and study-level meta-analysis for investigating modifiers treatment effect. Jpn J Clin Oncol 34(12):717-721,2004
45. Sakamoto J., Morita S., Kodera Y., Rahman M., Nakao A: Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 54(sup 1) :S25-S31,2004 46. Kato J., Sakamoto J., Teramukai S., Kojima H., Nakao A.:A prospective within-patient comparison clinical trial on the effect of parenteral cimetidine for improvement of fluid secretion and electrolyte balance in patients with short bowel syndrome. Hepato-Gastroenterology51:1742-1746,2004 47. Oda K., Akiyama S., Ito K., Kasai Y., Fujiwara M., Sekiguchi H., Nakao A., Sakamoto J.: Perioperative prostaglandin E1 treatment for the prevention of postoperative complications after esophagectomy: A randomized clinical trial. Surg Today 34:662-667, 2004 48. Matsui T., Kojima H., Suzuki H., Hamajima H., Nakazato H., Ito K., Nakao A., Sakamoto J.: Sialyl lewisa expression as a predictor of the prognosis of colon carcinoma patients in a prospective randomized clinical trial. Jpn J Clin Oncol 34(10):1-6 49. Konoshita T., Nashimoto A., Yamamura Y., Okamura T., Sasako M., Sakamoto J., Kojima H., Hiratsuka M., Arai K., Sairenji M., Fukushima N., Kimura H., Nakajima T.: Feasibility study of adjuvant chemotherapy with S-1(TS-1;tegafur,gimeracil,oteracil potassium)for gastric cancer. Gastric Cancer 7:104-109,2004 50. Ito K., Nakazato H., Koike A., Takagi H., Saji S., Baba S., Mai M., Sakamoto J., Ohashi Y.: Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer :A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis1 19:157-164,2004 51. Morita S., Ohashi Y., Hirakawa K., Nakata B., Saji S., Sakamoto J.: Phase / study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and /or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy. Jpn J Clin Oncol34(3)159-161,2004 52. Takahashi Y, Tanigawara Y., Sakamoto J., Takeuchi T., Mai M., Kubota T., Kitajima M., clinical trial of Komatsu Y., Togo T., Saji S.:A randomized phase Jpn J Clin Oncol 34(6):342-345,2004
tailored CPT-11+S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy. science. 53. Rahman M.., ,Sakamoto J., Fukui T.: Japan’s share of research output in basic medical Keio J Med 53(3):172-177,2004 54. Rahman M, Morita S., Fukui T., Sakamoto J.: Physicians’ choice in using internet and fax for patient recruitment and follow-up in a randomized controlled trial. Methods Inf Med 43:268-272, 2004 55. Rahman M., Uz-Zaman S., Sakamoto J., Fukui T.: How much do drug abusers pay for drugs in Bangladesh? J Health Popul Nutr 22(1):98-99,2004 56. Rahman M., Morita S., Fukui T., Sakamoto J.: Physicians’ choice in using internet and
fax for patient recruitment and follow-up in a randomized controlled trial. from Methods Inf Med 43:268-272,2004
Reprint
57. Yoshida K., Hirabayashi N., Takiyama W., Ninomiya M.,T akakura N., Sakamoto J., Nishiyama M., Yoge T.: Phase study of combination therapy with S-1 and Docetaxel (TXT)for advanced or recurrent gastric cancer. Anticancer Research 24: 58. Sakamoto J., Kondo Y., Takemiya S., ,2004 Japanese Sakamoto N., Nishisho I:A Phase
study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. Anti-Cancer Drugs 15:137-143, 2004 59. Sakamoto J. et al（Meta-analysis group of the Japanese society for cancer of the colon and rectum and the Mete-Analysis Group in Cancer）: Efficacy of oral adjuvant therapy after resection of colorectal cancer:5-year results from three randomized trials. J Clin Oncol 22(3):484-492,2004 60. Morita S., Toi M.,Kobayashi T., Ito Y., Hozumi Y., Ohno S., Iwata H., Sakamoto J.,: Application of a continual reassessment method to a phase clinical trial in capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. Jpn J Clin Oncol 34(2):104-106,2004 61. Sakamoto J et al: A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of Clinical Benefit Response for non-measurable type of gastric cancer. Jpn J Clin Oncol 33(5):238-240,2003 62. Ikawa O.,Takahashi S.,Kakihara N.,Shimotsuma M.,TakenakaA.,Sakamoto J. :S-1 prolongs the survival of patients with advanced gastric cancer and positive cytology. Cancer Research and Therapy11(1):121-127,2003 63. Sakamoto.J ,et.al: Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncol Rep 10:1081-1090, 2003 64. Morita S., Kobayashi K., Eguchi K., Matsumoto T., Shibuya M., Yamaji J., Sakamoto J., Ohashi Y.: Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer:application of a general linear model.Jpn J Clin Oncol 33(9):470-476,2003 65. Sakamoto J.: Neoadjuvant chemotherapy :a standard treatment for locally advanced gastric cancer in the near future? Gastric Cancer 6(3):131-133,2003 66. Takahashi Y., Takauchi T., Sakamoto J., Touge T.,Mai M.,Ohkura H.,Kodaira S., Olajima K.,Nakazato H.: The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients:a prospective clinical study. Gastric Cancer 6(3):142-145,2003 67. Rahman M., Sakamoto J., Fukui T.: Japan’s share of published research in ophthalmology. Jpn J Opthalmol 47:221-224,2003 68. Rahman M., Sakamoto J., Fukui T.: Biomedical research output in the last decade:Japanses perspectives. Japanese Society of General Medicine4(1):11-15 69. Inagaki H., Kurokawa T., Nonami T., Sakamoto J.: Hand –assisted laparoscopic left
lateral segmentectomy of the liver for hepatocellular carcinoma with cirrhosis. J Hepatobiliary Pancreat Surg 10:295-298,2003 70. Rahman M., Sakamoto J., Fukui T.:Conditional versus unconditional logistic regression in the medical literature. J of Clinical Rpidemiology 56:101-102,2003 71. Rahman M., Sakamoto J., Fukui T.: Publication in epidemiology journals:Japanses perspectives. J of Epidemiology13(2):96-97,2003 72. Rahman M., Sakamoto J., Fukui T.: Bidi smoking and oral cancer:a meta analysis. Int J Cancer 106:600-604,2003 73. Rahman M..,Sakamoto J., Fukui T.: Japan’s share of research output in urology and nephrology. International Journal of Urology 10:353-355,2003 74. Fukui T., Rahman M., Takeda K., Higaki J., Fukushima M., Sakamoto J., Morita S., Ogihara T., Fukiyama K., Fujishima M., Saruta T.: Candesartan antihypertensive survival evaluation in Japan(CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale,design ,and methods. Hypertens Res 26(12)979-990,2003 75. Sakamoto,J.,Teramukai,S.,Nakazato,H.,Sato,Y.,Uchino,J.,Taguchi,T.,Ryoma,Y., Ohashi,Y.,: Efficacy of Adjuvant immunochemotherapy with OK-432 for Patients Curatively Resected Gastric Cancer.: A Mete-Analysis of Centrally Randomized Controlled Clinical Trials. Journal of immunotherapy 25(5):405-412,2002 76. Kurokawa T.,Inagaki H., Sakamoto J., Nonami T.: Hand-assisted laparoscopic anatomical left lobectomy using hemihepatic vascular control technque. Surgical Endoscopy,2002 77. Inagaki H., Kojima H., Kato J., Kurikawa T., Yasue M.,Sakamoto J.,:Two sequential randomized phase Trials of combination chemotherapy with methorexate/5-Fluorouracil and cisplatin/5- Fluorouracil for advance pancreatic cancer. Cancer Research and Therapy10:107-120,2002 78. Sakamoto.J.: A new paradigm of chemotherapy for gastric cancer: Speeding up, and more clinical trials to catch up. Gastric Cancer 5:55-57,2002 79. Sakamoto, J., Teramukai,S.: Data Handling in Cancer Clinical Trials – How We Can Minimize Potential Biases. Jpn J Clin Oncol, 32(1)1-2,2002 80. Rahman M., Sakamoto J., Fukui T.: Japan’s contribution to nuclear medical research. Annals of Nuclear Medicine 16(6):383-385,2002 81. Rahman M.., Sakamoto J. ,Fukui T.: Japan’s share of articles in orthopedics. J Orthop Sci 7:607-609,2002 82. Rahman M.,Sakamoto J.,Fukui T.:Research output in anaesthesia: a quantitative ranking. Anaesthesia 57:1213-1214,2002 83. Sakamoto,J., Kodaira,S., Hamada,C., Ito,K., Maehara, Y., Takagi,H., Sugimachi,K., Nakazato,H, Ohashi,Y: An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral carmofur in patients with curatively resected colorectal cancer. Oncology Rep 8:697-703,2001
84. Sakamoto,J., Teramukai,S., Watanabe,Y., Hayata,Y., Okayasu,T., Nakazato,H.,
Ohashi,Y.,
for Japanese Meta-Analysis Group in Cancer; in: Japanese Society of Strategies for Cancer and Therapy : Meta-analysis Adjuvant Immunochemotherapy Using OK-432 in Patients With Resected Non-Small-Cell Lung Cancer. J.Immunother.,24(3)250-256,2001 85. Ichihara,T., Nomoto,S., Takeda,S., Nagura,H., Sakamoto,J., Kondo,K.,Horisawa,M., Nakao,A.: Clinical Usefulness of the Immunostaining of the Tumor Markers in Pancreatic Cancer.Hepato-Gastroenterogy,48:939-943,2001 86. Sakamoto, J., Kojima, H., Yasue, M., Hamashima, H., and Suzuki, H.: Organ- specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother pharmacol ., 45(suppl):S27-S32,2000 87. Matsui T., Kurosawa, N.,Hibi,K.,Akiyama,S., Kasai,Y., Sakamoto,J., Ito,K., Nakao,A., and Marumatsu,T.: The Ratio of splicing variants of MGC-24/CD 164, a sialomucin, correlates with the metastatic potential of colorectal carcinomas. J. Biochem., 127:1103-1107,2000 88. Obata,Y., Takahashi,T., Sakamoto,J., Tamaki,H., Tominaga,S., Hamajima,N., Chen,Y.-T., and Old,L.J.:SEREX analysis of gastric cancer antigens.Cancer Chemother. Pharmacol.,46(suppl):S37-S42,2000 89. Matsushima,S.,Sasaki,F.,Kinosada,Y.,Maeda,H.,Sogami,M.,Era,S.,Yatabe,Y., Miura,S., Ohashi,H., and Sakamoto,J.: Saturation transfer ratio Imaging in invasive ductal carcinomas of the breast. Magneic Resonance Imaging.,18:379-385,2000 90. Inagaki,H.,Nonami,T.,Kawagoe,T.,Miwa,T.,Hosono,J.,Kurokawa,T.,Harada,A., Nakao,A., Takagi,H., Suzuki,H.,and Sakamoto,J.: Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol.,35:235-239,2000 91. Kondo,K.,Sakamoto,J.,Nakazato,H.,Koike,A.,Kitoh,T.,Hachisuka,K.,Saji,S.,Yura,J.,Nimura, Y.,Hamajima.,M.,Katoh,K.,Yamaguchi,A.,Miya,K.,Yamauchi,M.,Mizuno,I.,Nagino,M.,and Takagi,H.: A phase Randomized study comparing doxifluridine and 5-fluorouracil as Supportive chemotherapy in advanced and recurrent gastric cancer. Oncology Rep.7:1-6,2000 92. Nonami,T.,Nakao,A.,Kurokawa,T.,Inagaki,H.,Matsushita,Y.,Sakamoto,J.,and Takagi,H.:Blood loss and ICG clearance as best prognostic markers of port-hepatectomy liver failure. Hepato-gastroenterology.,46:1669-1672(1999) 93. Sekiguchi,H.,Akiyama,S.,Fujiwara,M.,Nakamura,H.,Kondo,K.,Kasai,Y., Ito,K., Sakamoto,J.,and Takagi,H.:Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with Squamous cell carcinoma of the esophagus. Jpn J Surg.,29:97-101 (1999) 94. Inagaki,H.,Nonami,T.,Kurokawa,T.,Takeuchi,Y.,Okuda,N.,Nakao,A.,and Sakamoto,J.:Effects of nafamostat mesilate, a synthetic protease inhibior, on immunity and coagulation after hepatic resection. Hepato-gastroenterology., 46:3223-3228(1999) 95. Sakamoto,J.,Matsuyama,Y.,and Ohashi,Y.: An analysis of Jpn J Clin Oncol.,29(8):403-405(1999) institutional effects in a multicenter cancer clinical trial:is it also plausible from the clinicans’ point of view?
96. Uchida,T.,Wada,M.,and Sakamoto,J.: Developing bronchial fistulas as a late complication of extraperiosteal plombage. Jpn J Thorac Cardiovasc Surg 47(5):214-217(1999) 97. Kojima,H.,Sakamoto,J.,and Yasue,M.: Circadian rhythm-modulated chemotherapy with high dose 5-fluorouracil against gastrointestinal cancers:evaluation and case report. Nagoya J Me Sci., 62(1,2):29-38(1999) 98. Uchida,T.,Wada,M.,Sakamoto,J.,and Arai,Y.: Treatment for empyema with bronchopleural fistulas using endobronchial occlusion coils:Report of a case. Surg Today.,29:186-189(1999) 99. Saji,S.,Sakamoto,J.,Teramukai,S.,Kunieda,K.,Sugiyama,Y..,Ohashi,Y.,and Nakazato,H.:Impact of splenectomy and immunochemotherapy on survial following gastrectomy for carcinoma:Covariate interaction with immunosuppressive acidic protein, A serum marker for the host immune system. Surg Today.,29:504-510(1999) 100. Sakamoto,J.,Hamada,C.,Kodaira,S.,Nakazato,H.,and Ohashi,Y.: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer:Individual patient data meta-analysis of randomized tirals. Jpn J Clin Oncol.,29(2):78-86(1999) 101. Mtsuyama,Y.,Sakamoto,J.,and Ohashi,Y.:A Bayesian hierarchical survival model for the institutional effects in a multigentre cancer clinical trial.Stat Med.,17:1893-1908(1998) 102. Akiyama,S.,Sekiguchi,H.,Fujiwara,M.,Kasai,Y.,Ito,K.,Kondo,K., and Sakamoto,J.:Direct mediastinal injenction of DDS-CDDP prohibited local recurrence in the mediastinum in advanced esophageal cancer patients. Ann Cancer Res Ther.,7(2):97-99(1998) 103. Sakamoto,J.,and Yasue,M.:Do Japanese statistics on gastric carcinoma need to be revised?
Lancet.,349:1711-1712(1997)
104. Sakamoto,J.,Saji,S.,Koike,A.,Kojima,H.,and Nakazato,H.:More effective Prospective randomized clinical trial of adjuvant immunochemotherapy for curatively resected gastric cancer.-trial design focusing on subgroups of patients utilizing informations of subset analysis data from the previous trials. International gastric cancer congress.,27-30(1997) 105. Nakada,K.,Sakamoto,J.,Watanabe,T.,Itoh,K.,Akiyama,S.,and Takagi,H.: Imaging of recurrent intestinal carcinoma with Indium-111-labeled anti-carcinoembyonic antigen monoclonal antibody CEA102.Jpn J Cancer Res.,88:605-613(1997) 106. Sakamoto,J.,Teramukai,S.,Nakazato,H.,and Ohashi,Y.:A re-anaysis of a randomized clinical trial for gastric cancer using interval censoring. Jpn J Clin Oncol.,27(6):445-446(1997)
107. Sakamoto,J.,Kojima,H.,and Yasue,M.:Meta-analysis as a method of evaluating adjuvant
therapy for gastrointestinal cancer. Ann Caner Res Ther.,5(1):5-12(1996) 108. Garin-Chesa,P.,Sakamoto,J.,Welt,S.,Real,F.X.,Retting,W.,and Old,L.J.: organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy.
Int J Oncol.,9:465-471(1996)
109. Akiyama,S.,Ito,S.,Sekiguchi,H.,Fujiwara,M.,Sakamoto,J.,Kondo,K., Kasai,Y.,Ito,K.,and Takagi,H.:Preoperative embolization of gastric arteries for esophageal cancer.
Surgery.,9:542-546(1996)
110. Umeda,T., Sakamoto,J., Watanabe,T., Ito,K., Akiyama,S., Yasue,M., and Takagi,H. :Immunohistochemicdal analysis of the poorly defferntiated stomach adenocarcinoma with medullary growth pattern. J Surg Oncol.,62:34-39(1996) 111. Ichihara,T.,Suzuki,N.,Horisawa,M.,Kataoka,M.,Uchida,Y.,Sekiya,M., Matsui,T.,Hoshiang,C.,Sakamoto,J.,Nakao,A.,and Koide,A.: The importance of the real-time fluoroscopic intraoperative direct cholangiogram in the laparoscopic cholocystectomy using a new instrument. Hepatogastroenerol.,43:1296-1304(1996) 112. Sakamoto,J.,Teramukai,S..,Koike,A.,Saji,S.,Ohashi,Y.,and Nakazato,H.: Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma.
Cancer.,77(11):2206-2212(1996)
113. Fukushima,T.,Teramukai,K.,Asai,R.,Koyama,K.,Yasue,M.,Kido,C., and Sakamoto,J.:Colorectal carcinoma with stenosis;Findings on three-demensional helical CT using air contrast. Ann Cancer Res Ther.,5(1):43-47(1996) 114. Sakamoto,J.,Nakazato,H.,Teramukai,S.,Ohashi,Y.,Takahashi,Y.,Mai,M., Toge,T.,Okura,H.,Kodaira,S.,Maetani,S.,Okajima,K.,Hattori,T.,and Inokuchi,K.:Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. Surg Oncol., 133-139(1996) 115. Murayama,H.,Miura,K.,and Sakamoto,J.:Primary limitis plastica of the rectum:Report of four cases and review of the literature. Surg Today., 26:875-881(1996) 116. Uchida,T.,Nakagawaji,K.,Sakamoto,J.,Kojima,H.,Murakami,H.,Kato,J., and Yasue,M.:The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas:Report of a case. Surg Today., 26:138-141(1996) 117. Sakamoto,J.,and Yasue,M.:Extensive lymphadenectomy for gastric patients:what can the results of one trial tell us? Lancet., 345(895):742-743(1995) 118. Akiyama,S.,Kodera,Y.,Sekiguchi,H.,Fujiwara,M.,Sakamoto,J.,Kondo,K., Ito,K.,and Takagi,H.:Preoperative intra-aortic ultrasonography to determine respectability in advanced esophageal cancer. Br J Surg., 82:1671-1674(1995) 119. Yasue,M.,Sakamoto,J.,Morimoto,T.,Yasui,K.,Kondo,N.,Kurimoto,K., Teramukai,S.,and Ohashi,Y.:Evaluation of the effect of pancreatic resection on advanced pancreatic cancer with special reference using hospital –free survival as a measure of quality of life. Jpn J Clin
Oncol., 25(2):37-45(1995)
120. Fukushima,T.,Tanehiro,K.,Asai,R.,Uchida,T.,Kojima,H.,Murakami,H., Ohashi,K.,Toda,N.,Yasue,M.,and Sakamoto,J.:Hemosuccus pancreaticus- Report of a case associated with cyst forming undifferentiated carcinoma of the pancreas and review of the literature. Ann Cancer Res Ther.,4(1): 33-37(1995) 121. Yamamura,Y.,Sakamoto,J.,and Kito,T.:Study on dissection of paraaortic lymph nodes in the treatment of gastric carcinoma. Proceedings of the XVIth Int Cancer
Congress.,1727-1731(1994)
122. Sakamoto,J.,Kato,T.,Yamamura,Y.,Hirai,T.,Kito,T.,Watanabe,T.,and
Yasue,M.:Radioimmunodetection of metastatic colorectal cancer with radiolabeled monoclonal antibody. Proceeding of the XVIth Int Cancer Congress.,1837-1841(1994) 123. Nakazato,H.,Ogawa,N.,and Sakamoto,J.:Immunotherapy as adjuvant treatment after curative resection of gastric of cancer. Lancet..,8917(34):274(1994) 124. Nakazato,H.,Koike,A.,Saji,S.,Ogawa,N.,and Sakamoto,J.:Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer.
Lancet.,8906(34):1122-1226(1994)
125. Sakamoto,J.,Watanabe,T.,Kito,T.,Yamamura,Y.,Kiriyama,Y.,Kannagi,R., Ueda,R.,Takagi,H.,and Takahashi,T.:Expression of neural cell adhesion molecule in normal gastric mucosa and in gastric carcinoid tumors. Eur J Surg Res., 26:230-239(1994) 126. Sakamoto,J.,Nakazato,H.,Koike,A.,Saji,S.,and Ogawa,N.: Chemoimmunotherapy as an effective adjuvant treatment after curative resection of gastric cancer. Cancer
Invest.,13(suppl):61(1994)
127. Yasue,M.,Sakamoto,J.,Teramukai,S.,Morimoto,T.,Yasui,K.,Kuno,N., Kurimoto,K.,and Ohashi,Y.:Prognostic values of preoperative and postoperative CEA and CA19-9 levels in pancreatic cancer. Pancreas., 9(6):735-740(1994) 128. Torii,A.,Harada,A.,Nakao,A.,Nonami,T.,Ito,M.,Sakamoto,J.,and Takagi,H.:Expression of Lewisxand sialyl-Lewisx antigens in intrahepatic cholangiocarcinoma. Ann Cancer Res
Ther.,3(2):91-96 (1994)
129. Ichihara,T.,Sakamoto,J.,Nakao,A.,Furukawa,K.,Watanabe,T.,Suzuki,S., Horisawa,M.,Nagura,H.,Lloyd,K.O.,and Takagi,H.:Expression of blood group related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva blycoprotein. Cancer.,71:71-81(1993) 130. Sakamoto,J.,Watanabe,T.,Teramukai,S.,Akiyama,S.,Morimoto,T.,Takagi, H.,Nakazato,H.,Ueda,R.,and Takahashi,T.:Distribution of adenosine deaminase binding protein in normal and malignant tissues of the gastrointestinal tract studied by monoclonal antibodies. J Surg Oncol., 52:124-134(1993) 131. Narita,T.,Funahashi,H.,Sato,Y.,Watanabe,T.,Sakamoto,J.,Takagi,H.: Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer.
Cancer.,71(10):3044(1993)
132. Sawada,M.,Takada,A.,Ohwaki,I.,Takahashi,N.,Tateno,H.,Sakamoto,J., and Kannagi,R:Specific expression of a complex sialyl Lewisx antigen on high endothelial venules of human lymph nodes:Possible candidate for l-Selectin ligand. Biochem Biophy Res
Commun., 1931(1):337-347(1993)
133. Torii,A.,Nakayama,A.,Harada,A.,Nakao,A.,Nonami,T.,Sakamoto,J., Watanabe,T.,Ito,M.,and Tagaki,H.:Expression of the CD15 antigen in hepatocellular carcinoma. Cancer., 71(12):3864-3867(1993) 134. Kobayashi,K.,Sakamoto,J.,Kito,T.,Yamamura,Y.,Koshikawa,T.,Fujita,M., Watanabe,T.,and Nakazato,H.:Lewis blood group-related antigen expression in normal gastric epithelium and
gastric carcinoma. Am J Gastroenerol., 88(6):191-924(1993) 135. Inoue,M.,Tajima,K.,Kito,T.,Sakamoto,J.,Yamamura,Y.,Sato,T.,Suzuki,R., Koshikawa,T.,Nakamura,S.,and Such,T.:Canges in histropathological features of gastric carcinoma over a 26 year period. J Surg Oncol., 53:256-260(1993) 136. Yasue,M.,Sakamoto,J.,Yasui,K.,Morimoto,T.,Miyaishi,S.,Kurimoto,K, Kuno,N.,Kido,C.,and Kawashima,M.:A randomized trial of intraoperative radiation therapy(IORT) vs IORT plus chemotherapy(MTX-5FU) for adenocarcinoma of the pancreas Cancer Res Ther
Oncol.,3(4):283-287 (1993)
137. Yamamura,Y.,Kito,T.,Sakamoto,J.,and Nakazato,H.:Is it correct whether pancreatosplenectomy is essential for dissection and removal of lymph nodes along the spplenic artery. Recent Advances in Management of Digestive Cancer.,294-296(1993) 138. Sakamoto,J.,Watanabe,T.,Kato,T.,Takagi,H.,and Kito,T.: Radioimmunolocalization of human colorectal carcinoma xenografts with F(ab’)2 fragment of an antisialyl Lewis a monoclonal antibody and clinical radioimmunoscintigraphy of recurrent rectal carcinoma patient.
Recent Advences in Management of Digestive Cancer.,294-296(1993)
139. Sato,K.,Watanabe,T.,Tadokoro,M.,Sakamoto,J.,Murakami,H.,Ito,K., Sakuma,S.,and Takagi,H.:Autoradiographic anlaysis of radiolabeled anti-carcinoembryonic antigen monoclonal antibody, CEA 102 in colorectal cancer using computed radiography. Jpn J
Cancer Res., 83:379-386(1992)
140. Sakamoto,J.,Kato,T.,Watanabe,T.,Murayama,H.,Wada,K.,Sato,K.,Takagi, Kondo,K.,Sasaki,F.,Kido,C.,Nakazato,H.,Ueda,R.,and Takahashi,T.: Detection of locally recurrent colorectal cancer with radiolabeled monoclonal antibody H-15. Jpn J Cancer Res., 83:1373-1381(1992) 141. Sakamoto,J.,Koike,A.,Saji,S.,Teramukai,S.,Ohashi,Y.,and Nakazato,H.: Preoperative serum immunosuppressive acidic protein(IAP) test for the prognosis of gastric cancer:A statistinal study of the effect of the biological response modifier PSK. Jpn J Surg.,22:530-536(1992) 142. Kondo,T.,Sakamoto,J.,Nakazato,H.:Alternating immunochemotherapy of advanced gastric carcinoma:A randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy.,3:287-295(1991) 143. Sakamoto,J.,Yasue,M.,Morimoto,M.,and Morita,K.:Intraoperative radiation therapy for advanced carcinoma of the pancreas. Intra-operative Radiation Therapy.,254-256(1991) 144. Uchida,Y.,Imaizumi,M.,Abe,T.,Sakamoto,J.,and Nagura,H.: Immunohistochemical localization of Lea, Leb, Lex, Ley, antigens in normal ploliferative and metaplastic bronchial mucosa. Acta Histichem Cytochem.,23:441-451(1990) 145. Ingaki,H.,Sakamoto,J.,Nakazato,H.,Bishop,A.,and Yura,J.:Expression of Lewisa, Lewisb,and sialated Lewisa antigens in early and advanced human gastic cancers. J Surg Oncol.,44:208-213(1990) 146. Welt,S., Diriki,C.R., Real,F.X., Yeh,S.., Garin-chesa,P., Finstand,C.L., Sakamoto,J., Cohen,A., Kemeny,N., Elizabeth,A.C., Oettgen,H.F., and Old,J.:Quantitative analysis of antibody
localization in human metastatic colon cancer:A phase I study of monoclonal antibody A33. J Clin Oncol.,18:1894-1906(1990) 147. Sakamoto,J.,Watanabe,T.,Tokumaru,T.,Takagi,H.,Nakazato,H.,and Lloyd,K.O.:Expression of Lewisa, Lewisb, Lewisx, Lewisy, sialyl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res.,49:745-752(1989) 148. Ichihara,T., Nakao,A., Sakamoto,J., Nonami,T., Harada,A., Watanabe,T., Takagi,H., and Nagura,H.:Applicaton of the immunoperoxidse method for rapid intraoperative pathological diagnosis of pancreatic cancer. J Surg Oncol.,40:8-16(1989) 149. Ichihara,T., Nagura,H., Nakao,A., Sakamoto,J., Watanabe,T., and Takagi,H.: Immunohistochemical localization of CA19-9 and CEA in pancreatic carcinoma and associated diseases. Cancer .,61:324-333(1988) 150. Suzuki,Y., Ichihara,T., Nakao,A., Sakamoto,J.,Takagi,H., and Nagura,H.: Serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer correlation with immunocytochemical localization of antigens in cancer cells. Hepato-gastoenterol.,3(35):128-135(1988) 151. Morimoto,T., Chikashige,T., Yamada,F., Sakamoto,J., Yasui,K., Yasue,M., Miyaishi,S., Kido,C., and Takagi,H. :Thermographic study of canine pancreaticoduodenal graft. Transpl Porc.,20:900-903(1988) 152. Akiyama,S., Amo,H., Watanabe,T., Natsuyama,M., Sakamoto,J.,Imaizumi, T., Ichihara,T., Kondo,T., and Takagi,H. :Caracterization fo three human gastric cancer cell lines, NU-GC-2, NUGC-3 and NU-GC-4. Jpn J Surg., 18(4):438-446(1988) 153. Morimoto,T., Sakamoto,J., Chikashige,T., Nishimura,M., Yasui,K., Yasue,M., Miyaishi,S., Uchida,K., Kanou,T., and Takagi,H. :Successful canine pancreaticoduodenal allotransplantation with cyclosporine and gabexate mesilate. Transpl Proc., 19:1318-1320(1987) 154. Cohn,K.H., Welt,S., Banner,W.P., Haringron,M., Yeh,S., Sakamoto,J., Cordoncardo,C., Daly,J., Kemeny,N., Cohen,A., Lloyd,K.O., Decosse,J.J., Oettgen,H.F., and Old,L.J. :Localization of radioiodinated monoclonal antibody in colorectal cancer. Arch Surg.,122:1425-1429(1987) 155. Sakamoto,J., Watanabe,T., Morimoto,T., Takagi,H., and Nakazato,H.: Immunoanatomic distribution of blood group antigens in human gastric carcinoma. J Tumor Marker Oncol.,2:305-313(1987) 156. Watanabe,T., Nishikimi,M., Akiyama,S., Sakamoto,J., Suzuki,H., Ichihashi,H., Ozawa,T., Kondo,T., and Takagi,H. :A stomach oncolectal antigen recognized by monoclonal antibody GC302. Jpn J Surg., 17(6):507-516(1987) 157. Sakamoto,J., Furukawa,K., Cordon-Cardo,C., Yin,B.W., Oettgen,H.F., Old,L.J., and Lloyd,K.O. :Expression of Lewisa, Lewisb, X and Y blood group antigens in uman colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res.,46:1551-1561(1986) 158. Morimoto,T., Nishimura,M., Chikashige,T., Sakamoto,J., and Takagi,H.: Pachological
investigation in canine pancreaticoduodenal allograft with ciclosporin. HLA in Asian Oceania.,3:1031-1034(1986) 159. Cordon-Cardo,C., Lloyd,K.O., Sakamoto,J.,Mcgroaty,M.E., Old.L.J., and Melamed,M.R. :Immunohisologic expression of blood group antigens in human gastrointestinal tract and in colonic carcinoma. Int J Cancer.,37:667-676(1986) 160. Allen-Mersh,T.G., Sakamoto,J., Cohn,K., Welt,S., Lloyd,K., Daly,J., Yeh,S., and Decosse,J.J. :HT 29-15, a new monoclonal antibody for radioimmunolocalization of colorectal cancer. Surgical Forum.,36:428-430(1985) 161. Furukawa,K., Clausen,H., Hakamori,S., Sakamoto,J., Look,K., Lundblao,A., Mattes,M.J., and Lloyd,K.O. :Analysis of the specificity of five murtine anti-blood group antigen monoclonal antibodies, including one that indentifies type 3 and type 4 antigen determinants. Biochemistry., 24:7820-7826(1985) 162. Akiyama,S., Imaizumi,M., Sakamoto,J., Ichimura,I., Kondo,T., Age,T. :Basal cell carcinoma with lung metastasis. Jpn J Surg.,15(3):215-220(1985) 163. Sakamoto,J., Yin,B., and Lloyd,K.O. :Analysis of the expression of H,Lewis X, Y and precursor blood group determinants in saliva and red cells using a panel of mouse monoclonal antibodies. Mol Immunol ., 21(11):1093-1098(1984) 164. Kondo,T., Sakamoto,J., Ichihashi,H., and Kamei,H. :Effect of alternation administration of PSK and carbaziliquinone in tumor-bearing mice. Jpn J Cancer Res.,72:293-299(1981) 165. Akiyama,S., Sakamoto,J., Suyama,M., Imaizumi,M., Ichihashi,H., and Kondo,T. :Esophageal cyst, a case report and a review of the literature. Jpn J Surg.,10:338-342(1980) 166. Sakamoto,J., Ichihashi,H., Kondo,T., Kamei,H., and Yamamura,Y. :The effect of large-dose intratumoral administration of OK-432 in advanved cancer patients. Nagoya J Med Sci.,42:27-36(1979) 167. Sakamoto,J., Ichihashi,H., Kondo,T., Kamei,H., and Imaizumi,M. :The effect of intravenous hyperalimentation on cell-mediated immunity. Jpn J Surg., 9:89-94(1978)
Invited Lectures
1. Sakamoto J.,Investigators meeting for Gastric Cancer : Bangkok,Thaikand,January 6,2005 2. Sakamoto J., China-Japan-Korea gastric cancer therapy seminar :Current situation and future direction for gastric cancer in Japan .Bangkok,Thaikand,January 10,2004 3. Sakamoto J., Investigators meeting for Gastric Cancer: Current perspectives and the future. Bangkok,Thaikand,January 12,2003 4. Sakamoto J., Surgical management of gastric cancer to set the standard right. Singapore Annual Oncology Symposium, Singapore, October 27,2002 5. Sakamoto J., Meta-Analysis of oral 5-FU and its pro-drugs, Hopital Henri Mondor, Paris, France, January 30, 2001 6. Sakamoto J., Interim Report of Phase I Humanized Monoclonal Antibody huA33 for Gastric Cancer. Ludwig Institute for Cancer Research, New York, U.S.A. March 20, 2001. 7. Sakamoto J., Multidisciplinary Treatment Modalities for Gastric Cancer, Institut Municipal d’Investigatio Medica, Barcelona, Spain, June 18, 2000
Presentation at International Meeting
1. N Nagata, T Kato, M Fujii, H Takemoto, K Kondo, Y Okuyama, H Tominaga, J Sakamoto, H Mishima, I Hyodo: Multicenter Phase II Study of FLOX for Metastatic Colorectal Cancer (CRC) patients in Japan; SWIFT3 study; 2008 ESMO Annual Meeting, SWEDEN. 2. S. Hazama, Y. Okuyama, T. Kato, K.-I. Takahashi, H. Nozawa, N. Okayama, Y. Hinoda, M. Oka, J. Sakamoto, H. Mishima; UGT1A1 *6 IS A PREDICTIVE MARKER OF SEVERE NEUTROPENIA FOR METASTATIC CRC PATIENTS RECEIVED FOLFIRI IN JAPAN;2008 ESMO Annual Meeting, SWEDEN. 3.
T. Yumiba, K. Oba, H. Iishi, H. Narahara, T. Morimoto, M. Nakamura, H. Imamoto, C. Kakutani, J. Sakamoto, H. Shiozaki: A multicenter phase II trial of paclitaxel for patients with ascites caused by advanced/recurrent gastric cancer, a new concept of clinical benefit response for non-measurable type of gastric cancer.; ASCO Gastrointestinal Cancer Symposium2008.
4.
N. Hirabayashi, T. Yoshikawa, A. Tsuburaya, K. Yoshida, N. Nagata, Y. Kodera, N. Takahashi, K. Oba, S. Ishikura, J. Sakamoto: A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for patients with local symptoms due to unresectable primary advanced or locally recurrent gastric adenocarcinoma; ASCO Gastrointestinal Cancers Symposium2008,
5.
H. Mishima, Y. Okuyama, N. Nagata, T. Kato, K. Takahashi, H. Nozawa, H. Ando, M. Kobayashi, S. Hazama, J. Sakamoto: Multicenter phase II studies of FOLFIRI with reduced starting dose of irinotecan in metastatic CRC patients with homozygous for UGT1A1*28.; ASCO Gastrointestinal Cancers Symposium2008.
6.
K. Oba, S. Morita, T. Matsui, M. Kobayashi, K. Kondo, J. Sakamoto: An individual patient data meta-analysis of the immunochemotherapy using lentinan in patients with advanced gastric cancer.; ASCO Gastrointestinal Cancers Symposium2008.
7.
A. Tsuburaya, N. Murata, M. Kimura, Y. Ueda, M. Takahashi, S. Yoshino, M. Takagi, S. Morita, J. Sakamoto: Follow up of a multicenter phase II study of sequential paclitaxel and S-1 (TXL/S1) as postoperative adjuvant chemotherapy for gastric cancer (GC).; 2007 ASCO Annual Meeting.
8.
A. Tsuburaya, N. Murata, M. Kimura, Y. Ueda, M. Takahashi, S. Yoshino, M. Takagi, S. Morita, J. Sakamoto: Follow up of a multicenter phase II study of sequential paclitaxel and S-1 (TXL/S1) as postoperative adjuvant chemotherapy for gastric cancer (GC).; 2007 ASCO Annual Meeting
9.
Y. Shibata, K. Kondo, N. Nagata, T. Kato, Y. Okuyama, M. Ikenaga, H. Takemoto, K. Oba, J. Sakamoto, H.: Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1&2 study.; 2007 Gastrointestinal Cancers Symposium
10. K. Oba, S. Teramukai, M. Kobayashi, T. Matsui, H. Nakazato, K. Ito, J. Sakamoto: Efficacy of
adjuvant immunochemotherapy with polysaccharide k (PSK) for patients with curatively resected gastric cancer.; 2006 ASCO Annual Meeting
11. K. Yokoi, K. Omura, M. Hirano, T. Hara, Y. Munemoto, Y. Asada, J. Sakamoto: Phase 1 study
of paclitaxel, cisplatin, and 5-fluorouracil (TCF) in patients with advanced gastric cancer. ; 2006 ASCO Annual Meeting
12. Y. Ueda, H. Yamagishi, D. Ichikawa, J. Morii, N. Kakihara, T. Yamashita, H. Aragane, H.
Nishi, A. Chigusa, J. Sakamoto, Kyoto Gastrointestinal Cancer Chemotherapy Group: Phase II study of a combination of S-1 and weekly paclitaxel in patient with advanced or recurrent gastric cancer.; Phase II study of a combination of S-1 and weekly paclitaxel in patient with advanced or recurrent gastric cancer.; 2006 ASCO Annual Meeting
13. J. Sakamoto, A. Tsuburaya, S. Morita, T. Matsui, K. Oba, Y. Kodera, M. Kobayashi, K.
Yoshida, A. Nakao: Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomized clinical trials.; 2006 ASCO Annual Meeting
14. T. Kato, Y. Miyake, C. MCSGO (Multicenter Clinical Study Group of Osaka),, M. Ikenaga, H.
Mishima, M. Fukunaga, K. Murata, H. Ota, M. Sekimoto, J. Sakamoto, M. Monden: In-depth analysis of high effectivity in phase II study (irinotecan and doxifluridine, an intermediate form of capecitabine) for metastatic colorectal cancer: MCSGO, Colorectal Cancer Treatment Group.; 2006 ASCO Annual Meeting
15. S. Tominaga, T. Kato, M. Ikenaga, H. Mishima, M. Fukunaga, K. Murata, H. Ota, T. Ohnishi,
J. Sakamoto, M. Monden: Phase II study of irinotecan (CPT-11) and doxifluridine (5'-DFUR), an intermediate form of capecitabine, for metastatic colorectal cancer (MCRC), with survival results; 2006 ASCO Gastrointestinal Cancers Symposium
16. N. Nagata, A. Tsuburaya, M. Kimura, Y. Emi, N. Hirabayashi, M. Kobayashi, H. Itoh, J.
Sakamoto: A multicenter phase II study of sequential paclitaxel and S-1 (TXL/S-1) as postoperative adjuvant chemotherapy for gastric cancer (GC).; 2006 ASCO Gastrointestinal Cancers Symposium 17. Tominaga S.,Kato T.,Ikenaga M.,Mishima H.,Fukunaga M.,Murata K.,Ota H.,Ohnishi T., Sakamoto J., Monden M.: Phase study of irinotecan (CPT-11) and (MCRC),with survival results.;ASCO Gastrointestinal Cancer doxifluridine (5’-DFUR), an intermediate form of capecitabine, for metastatic colorectal cancer Symposium,San Francisco,California,Jan26-28,2006 18. Kojima H., Nonami T., Yamaguchi A., Manabe T., Fujii Y., Nimura Y., Sakamoto J., Nakao A.: Postoperative adjuvant chemotherapy in Japanese gastric cancer patients using Doxifluridine, an intermediate metabolite of Capecitabine, and 5-Fluorouracil -randomized controlled trial. ECCO 13 the European Cancer Conference , Paris,France,2005 19. Ninomiya M., Kondo L., Kojima H., Matsuo K., Hirabayashi N., Nakamura S., Kawamura S., Kobayashi M., Konno H., Sakamoto J.: Phase study of weekly Paclitaxel plus 5-fluorouracil
in patients with unresectable advanced or recurrent gastric cancer.; 41th ASCO Orlando,Florida,May13-17,2005 20. Nagata N., Tsuburaya A., Kimura M., Emi Y., Hirabayashi N. ,Kobayashi M., Itoh H., Sakamoto J.:A multicenter phase study of sequential and S-1(TXL/S-1)as postoperative adjuvant chemotherapy for gastric cancer(GC).; 41th ASCO Orlando,Florida,May13-17,2005 21. Yoshida K., Toge T., Ninomiya M., Takakura N., Hirabayashi N., Takiyama W., Sato Y., Terashima M., Goto M., Sakamoto J.: Phase study of S-1 and Docetaxel combination in advanced or recurrent gastric cancer.; 41th ASCO Orlando,Florida,May13-17,2005 22. Sakamoto J., Morita S., Tsuburaya A., Kodera Y., Matsui T., Kobayashi O.: Efficacy of adjuvant chemotherapy with oral fluorinated pyrimidines for patients with curatively resected gastric cancer. A meta-analysis of centrally randomized controlled clinical trials.; 41th ASCO Orlando,Florida,May13-17,2005 23. Ikenaga M., Kato T., Mishima H., Fukunaga M., Murata K., Tominaga S., Kano T., Morita S., Sekimoto M., Sakamoto J., Monden M.;A multicenter phase 2 study of Irinotecan(CPT-11) and Doxifluridine(5’-DFUR),an intermediate from of capecitabine, for metastatic colorectal cancer(MCRC). 41th ASCO Orlando,Florida,May13-17,2005 24. Hamada C., Sakamoto J., Yasutomi M.,Saji S., Nakazato H., Yoshida S., Kodaira K., Fujitani K.,Ohashi Y.,: An individual patients data meta-analysis of adjuvant chemotherapy with UFT ,in patients with curatively resected rectal cancer.; 41th ASCO Orlando,Florida,May13-17,2005 25. Kato T., Ikenaga M., Mishima H., Fukunaga M., Murata K., Takiuchi H., Yoshioka K., Furukawa H., Sakamoto J., Moden M.:A multicenter phase2 study of Irinotecan (CPT-11) and Doxifluridine (5’-DFUR),an intermediate form of capecitabine, for metastatic colorectal cancer (MRC). ASCO Gastrointestinal Cancers Symposium,2005 26. Nakata B., Tsuji A., Mitachi Y., Yamamitsu S., Hirata K., ShirasakaT., Sakamoto J., Saji S., Hirakawa K.: Is favorable survival to adverse effects during S-1 + low dose Cisplatin regimen(JFMC27-9902)for gastric cancer. : 6th International Gastric Cancer Congress,Yokohama,Japan,May4-7,2005 27. Kobayashi M., Okabayashi T., Okamoto K., Namikawa T., Ichikawa K., Kitaawa H., Sugimoto T., Sakamoto J., Araki K.: Pharmacokinetic study of Paclitaxel for the gastric cancer patients with peritoneal carcinomatosis.: 6th International Gastric Cancer Congress,Yokohama,Japan,May4-7,2005 28. Sakamoto J.: Current situation and future direction of adjuvant chemotherapy for gastric cancer.:19th World Congress of International Society for Digestive Surgery,Yokohama Japan, Dec8-11,2004 29. Sakamoto J., Hamada C., Yasutomi M., Saji S., Kato T., Nakazato H., Yoshida S.:An individual patient data meta-analysis of adjuvant therapy with uracil-ftorafur in patients with curatively resected rectal cancer. 29th ESMO Congress Vienna,Austria,Oct29-Nov2,2004 30. Sakamoto J., Oriuchi N., Mochiki E.,Scott M., Hoffman E., Jungbluth A., Asaso A., Kuwano
H., Endo K., Old L.J.:A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacokinetics, immunohistochemistry, and quantitative tumor uptake.: 40th ASCO New Orleans, LA, June5-8, 2004 31. Ueda U., Ymagishi H., Ichikawa D., Koizumi K., Morii J., Takenaka M., Shimotuma M., Kurioka H., Yamashita T., Sakamoto J.,: Phase June5-8, 2004 32. Kinouchi T., Sakamoto J.,Tsukamoto T., Akaza H., Kubote Y.,Ozono S., Kanenaka H.,Taguchi T., Koteke T.: Prospective randomized trial of natural interferon-alpha （ IFN ） versus IFN+cimetidine in advanced renal cell carcinoma with pulmonary metastasis. 40th ASCO New Orleans, LA, June5-8, 2004 33. Morita S., Kobayashi M., Ichihara T., Nakao A., Rahman M., Yamauchi M., Sakamoto J.: Truth-telling to patients with advanced cancer in Japan: A comparison between major centers and local hospitals. 40thASCO New Orleans, LA, June5-8, 2004 34. Kondo K., Chin K., Sakamoto J., Kojima h., Terashima M., Yamamura Y., Tsujinaka T., Hyodo I.,: Modified capecitabine regimen for advanced/metastatic gastric cancer: Final results from a multicenter phase trial.: ECCO, Copenhagen, Denmark,September21-25,2003 19. Koizumi W., Hyodo J., Sakamoto J., Terashima M., Ichikura T., Yamamura Y., Kondo K., Takiuchi H., Higashino M., Okayasu I.,: The effect of thymidine phosphorylase(TP) and dihydropyrimidine dehydrogenase (DPD) expression on response to capecitabine in patients with gastric cancer. ECCO Copenhagen, Denmark,September21-25,2003 20. Sakamoto J., Hamada C., Yasutomi M., Kodaira S., Kato T., Nakazato H., Ohashi Y.,: Efficacy of oral UFT as adjuvant chemotherapy after resection of rectal cancer:Mete- analysis of 5-year results from four randomized trials in 1815 patients.: 39th ASCO, Chicago, Illinois, May31-June3,2003 21. Koizumi W., Hyodo I., Sakamoto J., Terashima M., Ichikawa T., Yamamura Y., Kondo K., Takiuchi H., Higashino M., Ohashi Y.: Response to capecitabine according to thymidine phosphorylase(TP) and 22. dihydropyrimidine dehydrogenase (DPD) expression profiles in gastric cancer(GC):39th ASCO, Chicago, Illinois, May31-June3,2003 Kondo K., Chin K., Sakamoto J., Kojima H., Terashima M., Yamamura Y., Tsujinaka T., Hyodo I.:A multicenter phase trials using 4-weeks cycles of capecitabine in advanced/ metastatic gastric cancer(AGC): 39th ASCO, Chicago, Illinois, May31-June3,2003 23. Sakamoto J., Jungblut A., Matsui T., Nakanishi M., Kodera Y., Yamamura Y., Nakao A., Old LJ,: Expression of A33 antigen in specimens of the primary gastric cancer and of the recurrent tumor obtained from the same patients: 50th International Gastric Cancer Congress, Rome,Italy,2003 24. Kondo K., Nakao A., Nonami T., Yamaguti A, Saji S, Manabe T., Fujii Y., Nimura Y., study of a combination of S-1 and weekly Paclitaxel in patients with advanced or recurrent gastric cancer. :40thASCO New Orleans, LA,
Yamamura Y., Tanemura H., Tonouti Y., Sakamoto J.: Intermediate metabolite of Capecitabine , and5-flurouracil randomized controlled study employing thymidine phosphorylase and dihydropyrimidine dehydrogenase : 50th International Gastric Cancer Congress, Rome,Italy,2003 25. Ueda Y., Yamagishi H., Itoi H., Ichikawa D., Tamai H., Shiozaki A., Itoh N., Iwamoto A., Shimizu T., Sakamoto J.:A phase study of weekly Paclitaxel and TS-1 for advanced or recurrent gastric cancer: 50th International Gastric Cancer Congress, Rome,Italy,2003 26. Matsui T., Sakamoto J., Kojima H., Miyashita Y., Uemura T., Kojima T., Fujimitsu Y., Inagaki H.Kato J., Kondo K., Kodera Y., Nakao A.: Report of three cases with peritoneal dissemination of advanced gastric cancer who underwent combination chemotherapy using 5-FU plus paclitaxel ,and achieved a prolonged stable disease with excellent quality of life.: 50th International Gastric Cancer Congress, Rome,Italy,2003 27.Ogawa,K.,Sakamoto,J.,Yamamura,Y.,Nio.Y.,Taguchi,T.,Maehara,Y.,Si.Young.Kim, Masuda,N., Orita.,K.,Ohashi,Y.,:An Individual Patient Data Meta-Analysis of Adjuvant Immunochemotherapy with OK-432 after Curative Resection for Gastric Cancer. Annals of Oncology ESMO Congress,2002 28. Yashida,K.,Hirabayasi,N.,Yakiyama,W.,Ninomiya,M.,Takakura,N.,Sakamoto,J., Nishiyama,M.,Toge,T :The Japanses experiment in combining S-1 and taxotere®（docetaxel） . International Clinical Update Meeting on Gastrointestinal Cancer,2002 29. Sakamoto,J.,Nakazato,H.,Teramukai,S.,Yamamura,Y.,Nio,Y.,Tobe,T.,Ogawa.K.,Taguti,T., Maehara,Y.,Sugimati,K.,S.Y.Kim.,Sato,Y.,Utino,J.,Yokomoro,T.,Okinaga,K.,Ryoma,Y.,Ohashi Y.: An Individual Patient Data Meta-Analysis of Adjuvant Immunochemotherapy with OK-432 after Curative Resection for Gastric Cancer. 38th ASCO ,New Orleans,May,2002 30. Kurokawa,T.,Inagaki,H.,Sakamoto,J.,Nonami,T.: Hand-Assisted Laparoscopic anatomical left lobectomy using hemihepatic Vascular Control Technique. Surgical Endoscopy,2002. 31. Sakamoto J.,Hamada C.,Kodaira S,.Ito K.,Nkazato H.,Ohashi Y.,Yasutomi M.: An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer. 18th UICC International Cancer Congress,Oslo,Norway,June,2002 32. Hitoshi I.,Kurokawa Y.,Kojima H.,Kato J.,Sakamoto J., Nonami T.:Hand assisted laparoscopic hepatectomy for the tumor located posteror segment of the liver. SAGES,U.S.A, 2002 33 Sakamoto,J., Hamada,C., Yasutomi,M., Kodaira,S., Nakazato., Hoashi: Adjuvant Therapy with Oral Fluorinated Pyrimidines After Curative Resection for Colorectal Cancer:Individual Pationt Data Meta-Analysis of Randomized Trials. 37th ASCO,San Francisco,May,2001 34. Ito,K., Nakazato,H., Takagi,H., Saji,A., Koike,A., Baba,M., Mai,M., Sakamoto,J., Ohashi,Y: A Rondomized Clinical Trial on Adjuvant Immunochemotherapy with Protein Bound Polysaccharide K (PSK) After Curative Resection of Colon Cancer: Seven-Year Follow-Up Surgery. 37th ASCO,San Francisco,May,2001 35. Sakamoto.J.,Nakazato.H.，Kim S.Y.，Yamamura.Y.,Tobe.T.，Nio.Y.，Ogawa.K.，Taguc，
Utino.J.,Shirato.H.,Sato.Y.,Yokomori.T.,Yoshinaga.K..,Ohashi.Y.,: Adjuvant Immunochemotherapy with OK-432 After Curative Resection for Gastric Cancer： An Individual Patient Data Meta-Analysis. 4th International Gastric Cancer Congress,New York,April,2001 36. Sakamoto,J.,Hamashima,H.,Suzuki,H., Ito,K., Mai,M., Saji,S., Baba,S., Matsusihta,Y., Nakazato,H.: Sialyl-Lewisa Expression Predict Prognosis of Curatively Resected Colon Cancer Patients in an Adjuvant Immunochemotherapy Randomized Trial. : 92th AACR, New Orleans,March,2001 37. Sakamoto,J., Teramukai,S., Watanabe,Y., Hayata,Y.,Okayasu,T., Ikeda,T., Minani,N., Ide,K., Ishii,N., Hamada,C., Nakazato,H., Ohashi,Y.;:An Individual Lung Carcinoma.:36th ASCO,New Orleans,May,2000. 38. Sakamoto J., Fukushima M.,Hmashima H.,Suzuki H.,Ito K.,Mai M., Saji S.,Baba S.,Mtsushuma Y., Nakazato H.: Thymidylate synthese expression predict prognosis of curatively 39. resected colorectal carcinoma patients registered in an adjuvant immunochemotherapy clinical trial. 35th ASCO,Atlante,Georgia,May,1999 Nakazato H.,Ito K.,Takagi H.,Saji S.,Koike A.,Baba S.,Mai M.,Ohashi Y.,Sakamoto J.:A randomized clinical trial on adjuvant immunochemotherapy with protein bound polysaccharide K(PSK) after curative resection of colon cancer. 35th ASCO,Atlante,Georgia,May,1999 40. Ohashi Y., Sakamoto J.,Teramukai S.,Watanabe Y.,Okayadu T.,Hamada C.,Ichihara T.,Nakazato H.:Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small cell lung carcinoma. 35th ASCO,Atlante,Georgia,May,1999 41. Okabe H.,Fukushima M.,Ichihara T.,Hamashima H.,Sakamoto J.: Preparation and epitope analysis of monoclonal antibodies to recombinant human thymidylate synthase,and their application to clinical studies.90th AACR,Philadelphia,PA,April,1999 42. Sakamoto J.,Nakada K., Hmajima H., Ichihara T.,Suzuki H.,Yoshikawa K., Watanabe T: Radioimmunolocalization of colorectal carcinoma with indium-111 and technecium-99m-labeled anticarcinoembryonic antigen monoclonal antibody CEA102. 90th AACR,Philadelphia,PA,April,1999 43.Sakamoto J.,Teramukai S.,Ogoshi K.,Gochi A.,Kodera S.,Hamada C.,Nakazato H.,Ohashi Y: A tabulated and an individual patient data meta-analysis of adjuvant immunochemothrapy using polysaccharide K in patients with curativery resected gastric carcinoma. 3rd International Gastric Cancer Congress,Seoul,Korea,April,1999 Patient Data Meta-Analysis of Adjuvant Immunochemotherapy Using OK-432 in Patients with Resected Non-Small Cell